Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
India Leadership Commercial

Entrepreneurship Beckons As Eisai India Chief Departs

  • News

Executive Summary

Eisai Pharmaceuticals India's managing director has left the company and plans to start his own venture.

You may also be interested in...



Takeda Gets New India Chief, Mandate To Broaden Access

Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.

Cipla's COO Steps Down

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

More Top Level Pharma Exits In India As Cipla COO Departs

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

Table

View full table

Related Content

Generics Bulletin
Scrip
Scrip

Topics

Related Companies

Tags:
India Leadership Commercial
Latest Headlines

Stock Watch: How To Avoid Blockbuster Loss Of Exclusivity Bringing Your Company Down

ChatGPT Unleashed: Generative AI Use Cases Taking Off In Pharma

Pipeline Watch: 11 Approvals And 12 Phase III Readouts

BIO Notebook: GSK’s Walmsley On M&A; Merck On How Falling Valuations Are Affecting Deals

See All
UsernamePublicRestriction

Register

SC141225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By